Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Evaluate the activity and safety of Nab-paclitaxel in patients with sensitive or refractory
SCLC who relapsed after cisplatin or carboplatin and etoposide first-line chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Oncologico Italiano di Ricerca Clinica
Collaborators:
Clirest s.r.l. Istituto Toscano Tumori Istituto Toscano Tumori - Centro per il Coordinamento delle Sperimentazioni Cliniche Mipharm S.p.A. Temas srl